Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

A life sciences company is setting up shop in Durham to take advantage of the area's robust talent pool and thriving biotech ...

There’s a plum part in Celine Song’s forthcoming Materialists – the filmmaker’s first since her Oscar-nominated debut Past ...

AskBio Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that its Board of Directors has elected Independent Director Laura Sepp-Lorenzino, PhD, to the ...

Consequently, simple numerical quadrature schemes are found to be either of limited accuracy or slowly convergent with respect to increasing the sampling for self, edge- or vertex-adjacent source and ...

Over the past decade, several dozen cell and gene therapies have reached market in the U.S., bringing with them the promise of long-lasting benefits for serious diseases. Peter Marks’ fingerprints are ...

A rickety boat took me across the murky, brown waters of the mighty Mekong River from Chiang Saen in Thailand, with its giant golden Buddha perched on the hillside, to the Golden Triangle Special ...

Yet, the love triangle is appealing, thanks to the energetic performance from Sumukha, Rashika and Anjali. It is admirable to see a seasoned filmmaker attempting to reinvent his pet theme.

Organizers behind a pronatalist conference with far-right ties in Austin, Texas, this weekend have set up matchmaking events for attendees that include the option of getting married onsite as part ...

Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of thePhase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...